These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 15639107)

  • 1. Unfractionated heparin, low molecular weight heparins, and pentasaccharide: basic mechanism of actions, pharmacology, and clinical use.
    Bick RL; Frenkel EP; Walenga J; Fareed J; Hoppensteadt DA
    Hematol Oncol Clin North Am; 2005 Feb; 19(1):1-51, v. PubMed ID: 15639107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
    Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation.
    Hoppensteadt D; Walenga JM; Fareed J; Bick RL
    Hematol Oncol Clin North Am; 2003 Feb; 17(1):313-41. PubMed ID: 12627673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heparin and low molecular weight heparin in thrombosis and beyond.
    Mousa SA
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From unfractionated heparins to low molecular weight heparins.
    Hirsh J
    Acta Chir Scand Suppl; 1990; 556():42-50. PubMed ID: 1705072
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low- and ultra-low-molecular-weight heparins.
    Kakkar AK
    Best Pract Res Clin Haematol; 2004 Mar; 17(1):77-87. PubMed ID: 15171959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current trends in antithrombotic drug and device development.
    Fareed J
    Semin Thromb Hemost; 1996; 22 Suppl 1():3-8. PubMed ID: 8807721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on heparins at the beginning of the new millennium.
    Fareed J; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2000; 26 Suppl 1():5-21. PubMed ID: 11011802
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides.
    Ludwig RJ; Schindewolf M; Alban S; Kaufmann R; Lindhoff-Last E; Boehncke WH
    Thromb Haemost; 2005 Dec; 94(6):1265-9. PubMed ID: 16411404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generic low-molecular-weight heparins: some practical considerations.
    Fareed J; Leong WL; Hoppensteadt DA; Jeske WP; Walenga J; Wahi R; Bick RL
    Semin Thromb Hemost; 2004 Dec; 30(6):703-13. PubMed ID: 15630677
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology of the low-molecular-weight heparins.
    Fareed J; Hoppensteadt DA
    Semin Thromb Hemost; 1996; 22 Suppl 2():13-8. PubMed ID: 8946614
    [No Abstract]   [Full Text] [Related]  

  • 14. Differentiation of low-molecular-weight heparins: impact on the future of the management of thrombosis.
    Fareed J; Ma Q; Florian M; Maddineni J; Iqbal O; Hoppensteadt DA; Bick RL
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():89-104. PubMed ID: 15085470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Natural and synthetic glycosaminoglycans. Molecular characteristics as the basis of distinct drug profiles].
    Alban S
    Hamostaseologie; 2008 Feb; 28(1-2):51-61. PubMed ID: 18278163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Low-molecular heparins: their mechanism of action, pharmacology and clinical use].
    Bashkov GV; Kalishevskaia TM; Golubeva MG; Solov'eva ME
    Eksp Klin Farmakol; 1993; 56(4):66-76. PubMed ID: 8220023
    [No Abstract]   [Full Text] [Related]  

  • 17. New antithrombin-based anticoagulants.
    Desai UR
    Med Res Rev; 2004 Mar; 24(2):151-81. PubMed ID: 14705167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of heparin and low-molecular-weight heparins in the management of acute ischemic stroke.
    Padma V; Fisher M; Moonis M
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):405-15. PubMed ID: 16716101
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anticoagulant and antithrombotic effects of low molecular weight heparin].
    Bashkov GV; Kalishevskaia TM; Bako N
    Biull Eksp Biol Med; 1988 Oct; 106(10):399-402. PubMed ID: 2847825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins.
    Parody R; Oliver A; Souto JC; Fontcuberta J
    Haematologica; 2003 Nov; 88(11):ECR32. PubMed ID: 14607764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.